ESTEVE CDMO has announced a major strategic expansion in China, committing more than $80 million to relocate, modernize, and significantly scale its manufacturing operations in Shaoxing. This substantial capital investment underscores the company’s long-term commitment to bolstering its global footprint and enhancing its ability to meet the increasingly complex demands of small-molecule active pharmaceutical ingredient (API) development.
The new Shaoxing site represents a significant leap forward in ESTEVE CDMO’s Asian manufacturing capabilities. Designed to provide both scale and versatility, the facility incorporates advanced technological infrastructure aimed at accommodating both current market needs and future growth trajectories. Central to the site’s value proposition are specialized manufacturing processes—most notably spray drying and the production of highly potent APIs (HPAPI)—which have become critical requirements for modern, complex drug development.
Since establishing its presence in China in 2000, ESTEVE CDMO has consistently integrated its regional operations into a broader, interconnected network that spans Europe, the Americas, and Asia. The new Shaoxing facility is set to become a cornerstone of this strategy. The site features three primary manufacturing workshops equipped with a total reaction volume of 250 cubic meters. Furthermore, the company has reserved an additional 150 cubic meters for future expansion, bringing the total potential reaction volume to over 400 cubic meters. This design ensures that the company remains agile, allowing for rapid scaling as manufacturing requirements evolve.
“This investment is an important step in the sustained growth of ESTEVE CDMO’s global manufacturing platform,” said Joan Petit, President of ESTEVE CDMO. “It allows us to bring our capabilities closer to customers in Asia while leveraging the expertise of our global network. Our ambition is clear: build a leading global CDMO business with the capabilities and flexibility to support our partners worldwide. This is what drives us: making a difference for patients and contributing to our shared purpose of improving lives together.”
Beyond production capacity, the company has prioritized sustainable development and operational safety. The new facility has already earned a “Very Good” rating from the Building Research Establishment Environmental Assessment Method (BREEAM). This accreditation highlights the integration of rigorous environmental, health, and safety (EHS) standards into the facility’s core architecture and daily operations.
By aligning state-of-the-art technological capabilities with a robust, sustainable infrastructure, ESTEVE CDMO is positioning itself to better serve its international partners. As small-molecule APIs become more technically demanding to produce, this strategic expansion provides the necessary resources to navigate the evolving pharmaceutical landscape while maintaining a steady focus on the company’s mission of improving patient outcomes on a global scale.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
